Literature DB >> 27817868

Occurrence of phthalate esters in over-the-counter medicines from China and its implications for human exposure.

Lu-Lu Jia1, Xiang-Ying Lou2, Ying Guo3, Kelvin Sze-Yin Leung4, Eddy Y Zeng1.   

Abstract

Food, air, personal care products and indoor dust have been recognized as the main routes of exposure to phthalates in Chinese population, but other sources may have been overlooked, e.g., medicines. To fill the knowledge gap, phthalate esters were measured in 96 over-the-counter medicines made in China, including selected 71 Chinese patented medicines and 25 western medicines. It was found that none of the medicines was free of phthalates. The mean concentrations of individual phthalates ranged from 0.001μg/g (dicyclohexyl phthalate) to 5.85μg/g (diethyl phthalate). Among 9 targeted phthalates, di-n-butyl phthalate was the dominant congener, accounting for >65% of the total phthalates in all medicine samples, followed by di-(2-ethylhexyl) phthalate and diethyl phthalate. Phthalates in medicines appeared to derive from gastroresistant film coatings, plastic packing materials or phthalate contaminated rural herbal plants (especially for Chinese patented medicines). Daily human exposure to phthalates was estimated for local patients for one treatment cycle (e.g., one week) based on suggested consumption dosage and phthalate concentrations. Almost all exposure levels were below the guidelines suggested by the United States Environmental Protection Agency or European Food Safety Authority, indicating low health risk with phthalates from consumption of the medicines. In addition, concentration levels of phthalates in patients would increase upon administration but are expected to decrease to the same values as those in patients before they took medicines in several days. Because the number of medicine samples was limited and the concentrations of phthalates varied in a large range, further investigations are needed to acquire more data for better assessment of human health effects for Chinese population. Capsule: Distribution of phthalate esters in over-the-counter medicines and related exposure for Chinese population are examined. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chinese population; Di-n-butyl phthalate; Human exposure; Over-the-counter medicine; Phthalate esters

Mesh:

Substances:

Year:  2016        PMID: 27817868     DOI: 10.1016/j.envint.2016.10.025

Source DB:  PubMed          Journal:  Environ Int        ISSN: 0160-4120            Impact factor:   9.621


  4 in total

1.  Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men.

Authors:  Feiby L Nassan; Tim I M Korevaar; Brent A Coull; Niels E Skakkebæk; Stephen A Krawetz; Molly Estill; Elizabeth J Hait; Joshua R Korzenik; Jennifer B Ford; Ralph A De Poortere; Maarten A Broeren; Alan C Moss; Thomas R Zoeller; Russ Hauser
Journal:  Int J Hyg Environ Health       Date:  2018-08-28       Impact factor: 5.840

2.  A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and serum reproductive hormones in men.

Authors:  Feiby L Nassan; Brent A Coull; Niels E Skakkebaek; Anna-Maria Andersson; Michelle A Williams; Lidia Mínguez-Alarcón; Stephen A Krawetz; Janet E Hall; Elizabeth J Hait; Joshua R Korzenik; Jennifer B Ford; Alan C Moss; Russ Hauser
Journal:  Environ Res       Date:  2017-10-01       Impact factor: 6.498

3.  Phytochemical Profiles and Antimicrobial Activities of Allium cepa Red cv. and A. sativum Subjected to Different Drying Methods: A Comparative MS-Based Metabolomics.

Authors:  Mohamed A Farag; Sara E Ali; Rashad H Hodaya; Hesham R El-Seedi; Haider N Sultani; Annegret Laub; Tarek F Eissa; Fouad O F Abou-Zaid; Ludger A Wessjohann
Journal:  Molecules       Date:  2017-05-08       Impact factor: 4.411

4.  The effects of medicines availability and stock-outs on household's utilization of healthcare services in Dodoma region, Tanzania.

Authors:  August Kuwawenaruwa; Kaspar Wyss; Karin Wiedenmayer; Emmy Metta; Fabrizio Tediosi
Journal:  Health Policy Plan       Date:  2020-04-01       Impact factor: 3.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.